BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol Dial Transplant 2020;35:298-303. [PMID: 29992261 DOI: 10.1093/ndt/gfy225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
2 Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 2019;4:1568-76. [PMID: 31890998 DOI: 10.1016/j.ekir.2019.07.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
3 Alashkar F, Vance C, Herich-Terhürne D, Turki AT, Schmitz C, Bommer M, Hüttmann A, Dührsen U, Vogel U, Röth A. Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition. Vaccine 2019;37:6682-7. [PMID: 31562002 DOI: 10.1016/j.vaccine.2019.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Mülling N, Rohn H, Vogel U, Claus H, Wilde B, Eisenberger U, Kribben A, Witzke O, Gäckler A. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. Biosci Rep 2020;40:BSR20200177. [PMID: 32159209 DOI: 10.1042/BSR20200177] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019;12:333-7. [PMID: 31198225 DOI: 10.1093/ckj/sfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
6 Muldur S, Vadysirisack DD, Ragunathan S, Tang Y, Ricardo A, Sayegh CE, Irimia D. Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. Front Immunol 2021;12:777932. [PMID: 34899737 DOI: 10.3389/fimmu.2021.777932] [Reference Citation Analysis]
7 Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice. BMC Nephrol 2019;20:424. [PMID: 31752725 DOI: 10.1186/s12882-019-1599-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. Am J Kidney Dis 2020;75:417-25. [PMID: 31585683 DOI: 10.1053/j.ajkd.2019.06.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
9 Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Front Immunol 2021;12:747594. [PMID: 34691058 DOI: 10.3389/fimmu.2021.747594] [Reference Citation Analysis]